


CLAIMS

What is claimed is:

1. Use of a compound of Formula I:



wherein:

R¹ is C(R²)(R³)(R⁴);

R² is hydrogen, -OH or halogen;

R³ is hydrogen, -OH, halogen or C₁₋₈ alkyl;

R⁴ is halogen, C₁₋₈ alkyl, substituted C₁₋₈ alkyl, aryl, substituted aryl, alkylcycloalkyl or substituted alkylcycloalkyl;

R³ and R⁴ may join with the carbon to which they are attached to form a cycloalkyl ring, which may be optionally substituted, preferably with halogen and more preferably with one or more fluorine atoms;

R⁶ is hydrogen, C₁₋₈ alkyl, substituted C₁₋₈ alkyl, arylalkyl, substituted arylalkyl, alkylaryl, or substituted alkylaryl;

Z is optional, when present Z is -(CH₂)₁₋₈-, -C(=O)-, -S(=O)₂NH-, -S(=O)₂-, -C(=S)NH-, -S(=O)₂-CH₂-, C(=O)-NH-, -S(=O)₂-NR⁹-, -C(=O)C₁₋₈ alkylene or -C(=O)CH(NH₂)CH₂-;

R⁹ is hydrogen, C₁₋₈ alkyl or substituted C₁₋₈ alkyl;

R¹⁰ is hydrogen, C₁₋₈ alkyl or substituted C₁₋₈ alkyl;

R⁵ is hydrogen, C₁₋₈ alkyl, substituted C₁₋₈ alkyl, aryl, substituted aryl, C₁₋₈ alkenyl, substituted C₁₋₈ alkenyl, arylalkyl, substituted arylalkyl, alkylaryl, substituted alkylaryl, aminoarylalkyl or substituted aminoarylalkyl;


R⁷ is -OH or halogen; and

R^8 is hydrogen, halogen or C_{1-8} alkyl,

provided that R^2 and R^3 cannot both be hydrogen when R^4 is a halogen, Z is not present, R^7 is $-OH$, R^5 , R^6 and R^8 are hydrogen

in the manufacture of a medicament for treating a lysosomal storage disorder in a patient diagnosed with the same.

2. The use of claim 1, wherein the compound is of Formula II:



wherein:

R^1 is $C(R^2)(R^3)(R^4)$;

R^2 is hydrogen, $-OH$ or halogen;

R^3 is hydrogen, $-OH$, halogen or $-CH_3$;

R^4 is halogen, $-CH_3$, phenyl, fluorophenyl, methylphenyl, cyclohexylmethyl, wherein when R^4 is a halogen, both R^2 and R^3 cannot be hydrogen;

R^3 and R^4 may join with the carbon to which they are attached to form a cycloalkyl ring, which may be optionally substituted with one or more halogen atoms;

R^6 is hydrogen, phenylalkyl or substituted phenylalkyl;

Z is optional, when present Z is $-(CH_2)-$, $-C(=O)-$, $-S(=O)_2NH-$, $-S(=O)_2-$, $-S(=O)_2CH_2-$, $C(=O)-NH-$, $-S(=O)_2NR^9-$, $-C(=S)-NH-$ or $-C(=O)_2CH_2-$,

R^9 is hydrogen or CH_3 ;

R^{10} is hydrogen or CH_3 ;


R^5 is hydrogen or aminophenylalkyl;

R^7 is $-OH$ or halogen; and

R^8 is hydrogen, halogen or $-CH_3$,

provided that R^2 and R^3 cannot both be hydrogen when R^4 is halogen, Z is not present, R^7 is $-OH$, R^5 , R^6 and R^8 are hydrogen.

3. The use of claim 1, wherein the compound of Formula III:



wherein:

R^1 is $C(R^2)(R^3)(R^4)$;

R^2 is hydrogen, -OH or halogen;

R^3 is hydrogen, -OH, halogen or $-CH_3$;

R^4 is halogen, $-CH_3$, phenyl, fluorophenyl, methylphenyl, cyclohexylmethyl, wherein when R^4 is a halogen, both R^2 and R^3 cannot be hydrogen;


R^3 and R^4 may join with the carbon to which they are attached to form a cycloalkyl ring, which may be optionally substituted with one or more halogen atoms;











R^7 is -OH or halogen; and











R^8 is hydrogen, halogen or $-CH_3$,








provided that R^2 and R^3 cannot both be hydrogen when R^4 is a halogen, R^7 is -OH and R^6 and R^8 are hydrogen.








4. The use of a compound of:




























or a pharmaceutically acceptable salt, or solvate thereof, or any combination of two or more thereof in the manufacture of a medicament for treating a lysosomal storage disorder in a patient diagnosed with the same.

5. The use of Claim 4, wherein the compound is:




or a pharmaceutically acceptable salt, or solvate thereof.

6. The use of Claim 4, wherein the compound is:




or a pharmaceutically acceptable salt, or solvate thereof.

7. The use of Claim 4, wherein the compound is:




or a pharmaceutically acceptable salt, or solvate thereof.

8. The use of Claim 4, wherein the compound is:



or a pharmaceutically acceptable salt, or solvate thereof.

9. The use of Claim 4, wherein the compound is:




or a pharmaceutically acceptable salt, or solvate thereof.

10. The use of Claim 1, wherein the lysosomal storage disease is Niemann-Pick disease.

11. The use of Claim 1, wherein the lysosomal storage disease is Gaucher's disease.


12. Use of a compound



or a pharmaceutically acceptable salt, or solvate thereof in the manufacture of a medicament for treating Gaucher's disease in a patient diagnosed with the same.

Claims:

1. Use of a compound of Formula I:



wherein:

R¹ is C(R²)(R³)(R⁴);

R² is hydrogen or halogen;

R³ is hydrogen, halogen or C₁₋₈ alkyl;

R⁴ is halogen, C₁₋₈ alkyl, aryl, or alkylcycloalkyl;

R³ and R⁴ may join with the carbon to which they are attached to form a cycloalkyl ring, which may be optionally substituted with halogen and more preferably with one or more fluorine atoms;

R⁶ is hydrogen, C₁₋₈ alkyl, arylalkyl, or alkylaryl;

Z is optional, when present Z is $-(CH_2)_{1-8}-$, $-C(=O)-$, $-S(=O)_2NH-$, $-S(=O)_2-$, $-C(=S)NH-$, $-S(=O)_2-CH_2-$, $C(=O)-NH-$, $-S(=O)_2-NR^9-$, $-C(=O)C_{1-8}$ alkylene or $-C(=O)CH(NH_2)CH_2-$;

R⁹ is hydrogen, or C₁₋₈ alkyl;

R⁵ is hydrogen, C₁₋₈ alkyl, aryl, C₁₋₈ alkenyl, arylalkyl, alkylaryl, or aminoarylalkyl;


R⁷ is $-OH$ or halogen; and

R⁸ is hydrogen, halogen or C₁₋₈ alkyl,

provided that R² and R³ cannot both be hydrogen when R⁴ is a halogen, Z is not present, R⁷ is $-OH$, R⁵, R⁶ and R⁸ are hydrogen

in the manufacture of a medicament for treating a lysosomal storage disorder in a patient diagnosed with the same.

2. The use of claim 1, wherein the compound is of Formula II:



wherein:

R¹ is C(R²)(R³)(R⁴);

R² is hydrogen or halogen;

R³ is hydrogen halogen or -CH₃;

R⁴ is halogen, -CH₃, phenyl, fluorophenyl, methylphenyl, cyclohexylmethyl, wherein when R⁴ is a halogen, both R² and R³ cannot be hydrogen;

R³ and R⁴ may join with the carbon to which they are attached to form a cycloalkyl ring, which may be optionally substituted with one or more halogen atoms;

R⁶ is hydrogen, or phenylalkyl;

Z is optional, when present Z is -(CH₂)-, -C(=O)-, -S(=O)₂NH-, -S(=O)₂-, -S(=O)₂-CH₂-, C(=O)-NH-, -S(=O)₂NR⁹-, -C(=S)-NH- or -C(=O)₂-CH₂-,

R⁹ is hydrogen or CH₃;

R¹⁰ is hydrogen or CH₃;


R⁵ is hydrogen or aminophenylalkyl;

R⁷ is -OH or halogen; and

R⁸ is hydrogen, halogen or -CH₃,

provided that R² and R³ cannot both be hydrogen when R⁴ is halogen, Z is not present, R⁷ is -OH, R⁵, R⁶ and R⁸ are hydrogen.

3. The use of claim 1, wherein the compound of Formula III:



wherein:

R^1 is $C(R^2)(R^3)(R^4)$;

R^2 is hydrogen or halogen;

R^3 is hydrogen halogen or $-CH_3$;

R^4 is halogen, $-CH_3$, phenyl, fluorophenyl, methylphenyl, cyclohexylmethyl, wherein when R^4 is a halogen, both R^2 and R^3 cannot be hydrogen;




R^3 and R^4 may join with the carbon to which they are attached to form a cycloalkyl ring, which may be optionally substituted with one or more halogen atoms;


R^7 is $-OH$ or halogen; and








R^8 is hydrogen, halogen or $-CH_3$,







provided that R^2 and R^3 cannot both be hydrogen when R^4 is a halogen, R^7 is $-OH$ and R^6 and R^8 are hydrogen.








4. The use of a compound of:
















or a pharmaceutically acceptable salt, or solvate thereof, or any combination of two or more thereof in the manufacture of a medicament for treating a lysosomal storage disorder in a patient diagnosed with the same.

5. The use of Claim 4, wherein the compound is:




or a pharmaceutically acceptable salt, or solvate thereof.

6. The use of Claim 4, wherein the compound is:




or a pharmaceutically acceptable salt, or solvate thereof.

7. The use of Claim 4, wherein the compound is:




or a pharmaceutically acceptable salt, or solvate thereof.

8. The use of Claim 4, wherein the compound is:



or a pharmaceutically acceptable salt, or solvate thereof.

9. The use of Claim 4, wherein the compound is:




or a pharmaceutically acceptable salt, or solvate thereof.

10. The use of Claim 1, wherein the lysosomal storage disease is Niemann-Pick disease.

11. The use of Claim 1, wherein the lysosomal storage disease is Gaucher's disease.

12. Use of a compound



or a pharmaceutically acceptable salt, or solvate thereof in the manufacture of a medicament for treating Gaucher's disease in a patient diagnosed with the same.